Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease by Barrett Jeffrey C, Hansoul Sarah, Nicolae Dan L, Cho Judy H, Duerr Richard H, Rioux John D, Brant Steven R, Silverberg Mark S, Taylor Kent D, Barmada M Michael, Bitton Alain, Dassopoulos Themistocles, Datta Lisa Wu, Green Todd, Griffiths Anne M, Kistner Emily O, Murtha Michael T, Regueiro Miguel D, Rotter Jerome I, Schumm L Philip, Steinhart A Hillary, Targan Stephan R, Xavier Ramnik J, NIDDK IBD Genetics Consortium, Libioulle Cécile, Sandor Cynthia, Lathrop Mark, Belaiche Jacques, Dewit Olivier, Gut Ivo, Heath Simon, Laukens Debby, Mni Myriam, Rutgeerts Paul, Van Gossum André, Zelenika Diana, Franchimont Denis, Hugot Jean-Pierre, de Vos Martine, Vermeire Severine, Louis Edouard, Belgian-French IBD Consortium, Wellcome Trust Case Control Consortium, Cardon Lon R, Anderson Carl A, Drummond Hazel, Nimmo Elaine, Ahmad Tariq, Prescott Natalie J, Onnie Clive M, Fisher Sheila A, Marchini Jonathan, Ghori Jilur, Bumpstead Suzannah, Gwilliam Rhian, Tremelling Mark, Deloukas Panos, Mansfield John, Jewell Derek, Satsangi Jack, Mathew Christopher G, Parkes Miles, Georges Michel, Daly Mark J in Nature genetics (2008).

[PMID: 18587394] PubMed


Several risk factors for Crohn's disease have been identified in recent genome-wide association studies. To advance gene discovery further, we combined data from three studies on Crohn's disease (a total of 3,230 cases and 4,829 controls) and carried out replication in 3,664 independent cases with a mixture of population-based and family-based controls. The results strongly confirm 11 previously reported loci and provide genome-wide significant evidence for 21 additional loci, including the regions containing STAT3, JAK2, ICOSLG, CDKAL1 and ITLN1. The expanded molecular understanding of the basis of this disease offers promise for informed therapeutic development.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.